Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean surfaced nanotechnology (CSN) therapeutics. The company has a nanotechnology drug suspension; and engages in the development and commercialization of dietary supplements. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2 study for the treatment of stable multiple sclerosis; a Phase 2 biomarker study in Parkinson's; and Phase 2 and Phase 3 trials to investigate the potential for disease modification for neurodegenerative diseases. The company's products also include CNM-AgZn17, a topical gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat disease-causing infections, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. Clene Inc. is headquartered in Salt Lake City, Utah.
IPO Year:
Exchange: NASDAQ
Website: clene.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/4/2022 | Outperform → Perform | Oppenheimer | |
| 7/18/2022 | $16.00 | Buy | H.C. Wainwright |
| 5/2/2022 | $10.00 | Buy | Canaccord Genuity |
| 9/28/2021 | $20.00 | Outperform | Oppenheimer |
SALT LAKE CITY, March 16, 2023 (GLOBE NEWSWIRE) -- Clene, Inc. (NASDAQ:CLNN) along with its subsidiaries "Clene" and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced the appointment of Benjamin Greenberg, M.D., M.H.S. as Head of Medical. An internationally recognized expert in treating disorders of the central nervous system, Dr. Greenberg brings extensive clinical and research experience to Clene as the company continues its development of CNM-Au8® as a potential treatment for amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). "Dr. Green
SALT LAKE CITY, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) along with its subsidiaries "Clene" and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced the appointment of Morgan Brown as Chief Financial Officer effective Feb. 1, 2022. "Morgan joins the executive team at a pivotal time in Clene's growth," stated Clene's President and CEO, Rob Etherington. "He is a seasoned healthcare executive and public-company biopharma CFO, who has led the out-licensing of commercial stage assets and M&A transactions as well as numerous substantial equity and
SALT LAKE CITY, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) along with its subsidiaries "Clene" and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease using nanotechnology to treat energetic failure, today announced the appointment of Vallerie V. McLaughlin, MD, to its board as its seventh independent director. Dr. McLaughlin is the Kim A. Eagle MD Endowed Professor of Cardiovascular Medicine, Associate Chief Clinical Officer for Cardiovascular Services of the University of Michigan Medical Group, Associate Chief, Division of Cardiovascular Medicine, and Director of the Pulm
SALT LAKE CITY, May 19, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease using bioenergetic nanocatalysis, today announced the appointment of David J. Matlin as Chairman of the Board. He has served as a Director of Clene since 2020. Mr. Matlin is the Chief Executive Officer of MatlinPatterson Global Advisers, a global private equity firm he co-founded in 2002. Previously, he was a Managing Director at Credit Suisse First Boston and a founding partner of Merrion Group. He currently serve
4 - Clene Inc. (0001822791) (Issuer)
4 - Clene Inc. (0001822791) (Issuer)
4 - Clene Inc. (0001822791) (Issuer)
4 - Clene Inc. (0001822791) (Issuer)
Clene preparing for upcoming meeting in the second quarter with the U.S. Food and Drug Administration (FDA) to reach agreement on its statistical analysis plan (SAP) regarding analysis of neurofilament light chain (NfL) biomarker dataClene collecting NfL biomarker data from its large National Institute of Health (NIH)-sponsored Expanded Access Protocol (EAP), for evaluation in the third quarter to satisfy the FDA recommendation for additional NfL dataClene reported new data supporting the remyelination and neuronal repair associated with CNM-Au8® treatment in a late-breaking science session at the American Academy of Neurology (AAN) 2025 Annual MeetingClene released new data from a cross-reg
MIAMI, April 16, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 80th Emerging Growth Conference on April 16 & 17, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 - TodayApril 16, 2025 9:00Virtual Lobby opens.Register for the Conference. If you already registered, go back to t
MIAMI, April 15, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 81th Emerging Growth Conference on April 16 & 17, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1April 16, 2025 9:00Virtual Lobby opens.Register for the Conference. If you already register
SALT LAKE CITY, April 14, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company dedicated to advancing therapies for neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Emerging Growth Conference. Virtual Presentation DetailsDate: April 17, 2025Time of Presentation: 12:00 p.m. EDTFormat: Corporate update with Q&A A webcast of the presentation will be available on the "Events" section of the Clene website. Alternatively, one can register for and view the
Analyses of MRI and VEP data confirm anatomical and physiological improvements, indicating remyelination and neuronal repair in the brains of MS patients treated with CNM-Au8 during the long-term extension of VISIONARY-MSOver 90% of participants who showed improvements in cognition and vision also demonstrated corresponding improvements on MRI and visual electrophysiology tests SALT LAKE CITY, April 08, 2025 (GLOBE NEWSWIRE) -- Clene, Inc. (NASDAQ:CLNN) and its subsidiary, Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to advancing therapies for neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today anno
SALT LAKE CITY, April 01, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Jones Healthcare and Technology Innovation Conference and host 1x1 investor meetings. Date: April 9, 2025Time of Presentation: 11:30 am PT Location: Las Vegas, NV, Venetian Resort Format: Presentation 1x1 Meetings: Please contact your Jones representative. A webcast of the pr
Clene planning to submit a New Drug Application (NDA) in the second half of 2025 for potential Accelerated Approval of CNM-Au8® in ALSClene planning to initiate the confirmatory Phase 3 RESTORE-ALS trial in subjects with ALS in mid-2025Secured new $10.0 million debt facility at a lower interest rate to replace remaining outstanding $7.85 million debt balance with Avenue Capital Cash, cash equivalents and marketable securities of $12.2 million as of December 31, 2024, includes $7.3 million in gross proceeds raised on October 1, 2024Clene collecting and analyzing biomarker NfL data from its large NIH-sponsored Early Access Protocol (EAP), for evaluation in the third quarter to satisfy the U.S.
SALT LAKE CITY, March 12, 2025 (GLOBE NEWSWIRE) -- Clene, Inc. (NASDAQ:CLNN) and its subsidiary, Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced new evidence from a cross-regimen, post hoc analysis of long-term survival in HEALEY ALS Platform Trial participants. The analyses further substantiate that treatment with CNM-Au8® 30 mg delivers a significant survival benefit for people living with ALS. New Survival AnalysesThe analyses compared survival in participants who received CNM-Au8 30 mg (Regimen C)
SALT LAKE CITY, March 06, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will participate in a fireside chat at the 37th Annual Roth Conference and host 1x1 investor meetings. Date: March 18, 2025Time of Presentation: 9:20 am PSTFormat: Virtual Fireside Chat1x1 Meetings: Please contact your Roth representative. A webcast of the presentation will be available on the "E
Longitudinal ALS patient data from APST Research will enable a more robust analysis of the effect of CNM-Au8 on NfL biomarkersAPST Research data includes thousands of people living with ALS including clinical, survival, and longitudinal NfL data Clene plans to analyze the APST ALS NfL biomarker and clinical dataset to compare NfL change from its ongoing NIH-sponsored EAP to address the FDA's request for supportive evidence of CNM-Au8's effect on NfL reduction observed in the HEALEY ALS Platform TrialClene plans to submit a New Drug Application (NDA) in second-half 2025 SALT LAKE CITY, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries,
4 - Clene Inc. (0001822791) (Issuer)
4 - Clene Inc. (0001822791) (Issuer)
4 - Clene Inc. (0001822791) (Issuer)
4 - Clene Inc. (0001822791) (Issuer)
4 - Clene Inc. (0001822791) (Issuer)
4 - Clene Inc. (0001822791) (Issuer)
4 - Clene Inc. (0001822791) (Issuer)
4 - Clene Inc. (0001822791) (Issuer)
4 - Clene Inc. (0001822791) (Issuer)
4 - Clene Inc. (0001822791) (Issuer)
10-Q - Clene Inc. (0001822791) (Filer)
8-K - Clene Inc. (0001822791) (Filer)
424B5 - Clene Inc. (0001822791) (Filer)
8-K - Clene Inc. (0001822791) (Filer)
EFFECT - Clene Inc. (0001822791) (Filer)
DEFA14A - Clene Inc. (0001822791) (Filer)
DEF 14A - Clene Inc. (0001822791) (Filer)
8-K - Clene Inc. (0001822791) (Filer)
PRE 14A - Clene Inc. (0001822791) (Filer)
424B5 - Clene Inc. (0001822791) (Filer)
The primary endpoint of adjusted ALSFRS-R and secondary endpoints of CAFS and SVC were not met at 24 weeksPrespecified exploratory analyses of the secondary survival endpoint for the 30 mg dose demonstrated a >90% reduction in risk of death or risk of death/permanently assisted ventilation at 24 weeks Survival signal consistent with prior results from the Phase 2 RESCUE-ALS trialClene will continue the open-label extension of CNM-Au8 in the Healey ALS Platform Trial and is in discussions with the Healey & AMG ALS Center to design and offer an Expanded Access Protocol (EAP) of CNM-Au8 30mg for eligible participants of closed regimens and othersClene is pursuing multiple paths, including ongoi
SALT LAKE CITY, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) along with its subsidiaries "Clene" and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced that it will report topline results of the CNM-Au8® regimen of the HEALEY ALS Platform Trial on Monday, Oct. 3. Clene's management team will host a conference call and webcast to discuss the results. Conference Call and Webcast DetailsTime and Date: 8:30 a.m. EDT on Oct. 3, 2022Investors: 1 (888) 660-6179 (toll-free) or 1 (929) 203-1946 (toll)Conference ID: 5318408Webcast Link A live audio
CNM-Au8 met primary and secondary endpoints of Low Contrast Letter Acuity (LCLA) and modified Multiple Sclerosis Functional Composite (mMSFC) compared to placebo over 48 weeks in the mITT populationConsistent improvements favoring CNM-Au8 were seen across paraclinical biomarkers, providing physiological evidence for its potential neuroprotective and remyelinating effectsCNM-Au8 treatment was well-tolerated, and there were no significant safety findings reportedResults provide support to advance CNM-Au8 into Phase 3 clinical developmentClene to host a call and webcast at 7:30 am EDT today SALT LAKE CITY, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiarie
SALT LAKE CITY, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) along with its subsidiaries "Clene" and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced that it will present results from its Phase 2 VISIONARY-MS trial at 7:30 a.m. EDT on Monday, August 15. Conference Call and Webcast Details:Presentation Time: 7:30 a.m. EDT on August 15, 2022 Investors (Toll free): 1 (888) 770-7152Conference ID: 5318408Webcast link A live audio webcast can also be accessed by visiting the Investors section of the Company's website presentations page. A replay o
RESCUE-ALS Phase 2 Trial did not meet primary MUNIX biomarker endpoint or secondary FVC endpoint at week 36; MUNIX efficacy signal was observed at week 12 (p=0.057)MUNIX trial results demonstrated protection of lower motor neurons in the pre-specified subset of limb onset ALS subjects (Wk12, p=0.0385; Wk36, p=0.0741), which represents approximately 70% of the ALS populationStatistically significant reductions in clinically relevant outcomes including ALS disease progression (p=0.0125), ALSFRS-R responder analysis (p=0.035), and improved ALS specific quality of life (p=0.018)Evidence for potential long-term survival benefit Results for Healey ALS Platform Trial Expected in the Second Half of
SC 13G/A - Clene Inc. (0001822791) (Subject)
SC 13G - Clene Inc. (0001822791) (Subject)
SC 13D/A - Clene Inc. (0001822791) (Subject)
SC 13G/A - Clene Inc. (0001822791) (Subject)
SC 13G/A - Clene Inc. (0001822791) (Subject)
SC 13G/A - Clene Inc. (0001822791) (Subject)
SC 13G - Clene Inc. (0001822791) (Subject)
SC 13G/A - Clene Inc. (0001822791) (Subject)
SC 13G - Clene Inc. (0001822791) (Subject)
SC 13G - Clene Inc. (0001822791) (Subject)
Oppenheimer downgraded Clene from Outperform to Perform
H.C. Wainwright initiated coverage of Clene with a rating of Buy and set a new price target of $16.00
Canaccord Genuity initiated coverage of Clene with a rating of Buy and set a new price target of $10.00
Oppenheimer initiated coverage of Clene with a rating of Outperform and set a new price target of $20.00
Maxim Group initiated coverage of Clene with a rating of Buy and set a new price target of $18.00
Cantor Fitzgerald initiated coverage of Clene with a rating of Overweight and set a new price target of $22.00
Benchmark initiated coverage of Clene with a rating of Buy and set a new price target of $25.00
Benchmark initiated coverage of Clene with a rating of Buy and set a new price target of $25.00
Benchmark initiated coverage of Clene with a rating of Buy
Roth Capital initiated coverage of Clene with a rating of Buy and set a new price target of $24.00